Proceedings Of Recurrent Ovarian Cancer

Approximately 75% of ovarian carcinoma are diagnosed in advanced International Federation of Gynecology and Obstetrics stage III disease,most of this case will recur even with primary cytoreductive surgery or debulking procedure followed by systemic chemotherapy.The knowledge of distinct recurring and prognostic indicators help us diognosis relapse earlier.Many studies have shown that clinicopathological factors(tumor stage,histologic grade,histologic type,residual disease after primary surgery,et al).have prognostic significance.Others are discussed,such as node status, different route of neoadjuvant chemotherapy and intraperitoneal (IP)chemotherapy.It's important component part of patient management to monitor disease status among ovarian cancer patients after primary treatment.Routine surveillance include physical examination (pelvic exam),serum cancer antigen 125 (CA-125) levels,computed tomography (CT), magnetic resonance imaging(MRI),ultrasound examination. Recently, positron emission tomography(PET) may increase diagnostic confidence for the detection of recurrent disease.Treatment of recurrent disease is palliative and is initiated with the goals of controlling disease-related symptoms,limiting treatment-related toxicity,maintaining or improving quality of life,delaying time to progression,and prolonging survival.Treatment for recurrent ovarian carcinoma mainly involves second-line chemotherapy and secondary cytoreductive surgery still,but there are some advances in surgical techniques and the introduction of novel chemotherapeutic agents.Within the last few years,biotherapy have been rapidly developed.Immunotherapeutic and gene therapy have been a promising strategy for cancer treatment.